NeuroDigm's Model Reveals The Reversal Of Chronic Pain

[Guest guest]

NeuroDigm's Model Reveals The Reversal Of Chronic Pain

http://www.medicalnewstoday.com/articles/96338.php

Hannaman MD, president of NeuroDigm Co. in Fort Worth, Texas has

confirmed that a recombinant human erythropoietin, epoetin alfa, can

reverse neural changes that cause chronic pain behavior. Using their

Biogenic Model of Chronic Pain™, epoetin alpha was applied once

locally in micro doses to the affected nerves resulting in the

reversal of pain behaviors permanently.

Many types of chronic pain are resistant to treatments, needing

opiates, oral drugs, anesthetic blocks, and spinal pumps or spinal

stimulators to control the pain. Some may even have the identified

nerve cut to attempt to relieve pain. Dr. Hannaman says that

NeuroDigm's animal model can transform the future for chronic pain

patients by predicting the realistic clinical efficacy of drugs and

biopharmaceuticals and enable more targeted treatments with less side

effects.

NeuroDigm has developed their model to give the biotechnology,

pharmaceutical and research industries a more realistic model by

correlating the development of the model with the process of human

tissue repair. Dr. Hannaman says many chronic pain conditions develop

gradually after an injury as the tissue repairs itself and have no

evidence of nerve damage.

The animal studies are supported by Dr. Hannaman's clinical

experience with chronic pain patients. After identifying the specific

nerve involved in a patient's pain, a single application

percutaneously of very small doses of epoetin alpha to an identified

site of neural inflammation can rapidly and permanently reverse the

associated pain behavior including mechanical allodynia. Localized

treatments have been performed with epoetin alpha in patients on many

peripheral nerves including the sciatic nerve, lateral femoral

cutaneous nerve and spinal accessory nerves.

NeuroDigm is a private R & D company in Fort Worth, Texas. NeuroDigm

licenses proprietary models (US Patent 7015371) to enable the

development of more effective treatments for chronic nerve pain.

Medical devices to help in the clinical diagnosis of chronic pain are

also being developed.

http://www.neurodigm.com